The abstract is read at the publisher; the summary is JClub's.
Bacteriophage-derived endolysins show selective antistaphylococcal activity in preclinical work, but early clinical evidence in atopic dermatitis remains mixed, limiting certainty about benefit.
- Why it matters: Chronic itch in atopic dermatitis is linked to cutaneous dysbiosis and expansion of Staphylococcus aureus, which can amplify type 2 inflammation and sensory neuron activation. Broad antimicrobials may worsen commensal loss, motivating targeted alternatives like endolysins.
- What they did: This review explains endolysin mechanisms—peptidoglycan cleavage and rapid lysis of susceptible bacteria without requiring active growth—and summarizes how variable antimicrobial spectra affect outcomes. It also assesses early clinical findings and key practical uncertainties, including formulation and patient selection.
- The result: The evidence supports considering endolysins as part of microbiome-directed strategies, but unresolved issues include inflammation from rapid bacterial breakdown and persistence of toxins after killing. The review concludes they should be weighed alongside approaches such as topical bacteriotherapy with protective commensals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.